DiPasquale H, Rassaert C, Welaj P, Gingold J
Agents Actions. 1975 Feb;5(1):52-6. doi: 10.1007/BF02027159.
Liver function alterations, in the adjuvant induced polyarthritis procedure in rats, has been demonstrated by many investigators. We observed a significant inhibition of the polyarthritis with phenylbutazone but we were unable to find any changes in the relative liver weights of SGPT, AP or BUN in polyarthritic or phenylbutazone treated rats. However, we did observe that polyarthritic rats maintained a significantly higher plasma phenylbutazone concentration than the corresponding non-arthritic controls. This appears to futher substantiate the influence of 'pathopharmacodynamics' on the disposition and activity of drugs.
许多研究者已证实,在大鼠佐剂诱导性多关节炎实验中会出现肝功能改变。我们观察到保泰松对多关节炎有显著抑制作用,但在患多关节炎的大鼠或用保泰松治疗的大鼠中,我们未能发现其相对肝脏重量、血清谷丙转氨酶(SGPT)、碱性磷酸酶(AP)或血尿素氮(BUN)有任何变化。然而,我们确实观察到,患多关节炎的大鼠血浆保泰松浓度显著高于相应的非关节炎对照大鼠。这似乎进一步证实了“病理药效学”对药物处置和活性的影响。